MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
Burning Rock Biotech Limited Revenue 2011-2026 | BNR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 508 M | 430 M | 382 M | 209 M | 111 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 508 M | 111 M | 328 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 74.6 | -1.49 % | $ 5.03 B |  USA |
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
568 M | $ 9.28 | 3.11 % | $ 618 M | USA |
|
Biodesix
BDSX
|
71.3 M | $ 15.5 | 5.51 % | $ 2.01 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 465.57 | 1.89 % | $ 13.4 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.7 | 0.86 % | $ 435 M | USA |
 |
National Research Corporation
NRC
|
137 M | $ 17.38 | -0.77 % | $ 389 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.39 | - | $ 417 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 160.55 | 1.56 % | $ 7.96 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 168.36 | 0.81 % | $ 28.9 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.21 | -17.22 % | $ 6.59 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 268.55 | 2.27 % | $ 26.1 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
46.9 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 126.25 | 1.99 % | $ 20.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
15.2 M | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 7.73 | 1.58 % | $ 458 M | USA |
 |
RadNet
RDNT
|
2.04 B | $ 59.61 | -3.45 % | $ 4.48 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 266.82 | 0.88 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.74 | 1.81 % | $ 281 M | USA |
 |
Sotera Health Company
SHC
|
1.16 B | $ 13.89 | 0.07 % | $ 3.94 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 3.49 | 0.29 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 7.94 | -1.98 % | $ 1.02 B | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | $ 30.98 | -2.33 % | $ 1.57 B | USA |
 |
Natera
NTRA
|
820 M | $ 197.02 | -1.53 % | $ 19.4 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.95 | 2.22 % | $ 957 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.49 | -6.88 % | $ 98.3 M | USA |
 |
OPKO Health
OPK
|
184 M | $ 1.14 | -1.3 % | $ 791 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 25.59 | -0.62 % | $ 711 M | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 7.99 | 6.53 % | $ 31.8 M | Israel |
 |
DexCom
DXCM
|
4.66 B | $ 66.84 | 1.36 % | $ 26.1 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | $ 104.91 | - | $ 19.8 B | USA |